Although the incidence of IDH1/2 mutations is only 0.4%‐1.1% in NSCLCs, it is worthwhile to investigate IDH1/2 inhibitors because of the high prevalence of lung cancers in the United States and worldwide. The gene discussed is IDH1; the disease is lung cancer.